Makary’s FDA Reforms Continue to Advance Amid Leadership Turmoil on May 26, 2026 Advisory Committees artificial dyes Biological Factors conflict of continuous trial gene therapy GRAS Leadership Makary National Priority Vouchers reforms United States Food and Drug Administration +
Congressional 2026 Spending Bill Advances PBM Reforms in Medicare Part D on January 21, 2026 appropriations Commercial Managed Care - Pharmacy Benefit Manager funding bill government Medicare Part D reforms +